Related Experiment Video
Updated: Jun 14, 2026
10:36
Rare Event Detection Using Error-corrected DNA and RNA Sequencing
Published on: August 3, 2018
Benchmarking Q40 sequencing for sensitive and efficient detection of rare genomic variants
Shumeng Duan1, Yaqing Liu1, Xiaorou Guo1
1State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.
Genome Biology
|June 13, 2026
Summary
New Q40 sequencing technology significantly improves the detection of low-frequency genetic variants, offering higher sensitivity and reproducibility. This advancement enhances accuracy and reduces costs for applications like precision oncology.
Area of Science:
- Genomics
- Molecular Biology
- Bioinformatics
Background:
- Phred quality score (Q score) is crucial for DNA sequencing accuracy.
- The impact of Q40 sequencing (99.99% accuracy) on detecting subtle biological variations needs validation.
Purpose of the Study:
- To benchmark Q40 sequencing technology against the standard Q30.
- To evaluate Q40's effectiveness in detecting germline and somatic variants, including low-frequency mutations and copy number variations.
- To assess the impact of Q40 sequencing on cost-effectiveness and sample volume.
Main Methods:
- Utilized diverse DNA/RNA reference materials (Quartet, NIST-RM8398, SEQC2-HCC1395/BL, MAQC, ERCC).
- Compared Element AVITI (Q40) with Illumina NovaSeq 6000 (Q30).
- Analyzed variant detection accuracy, sensitivity for low-frequency mutations, CNV reproducibility, and signal-to-noise ratio.
Main Results:
- Q40 sequencing reduced required depth by 33.3% for germline and somatic variants.
- Sensitivity for low-frequency somatic mutations (VAF ≤ 0.2) increased by 33.3%.
- CNV detection reproducibility improved sixfold (60.3% vs. 10.4%) with Q40 at 30× depth.
- Q40 enhanced sample discrimination by 13.1% SNR and reduced per-sample volumes by 33.3-60%, potentially lowering costs by 2.2-31.7%.
Conclusions:
- Q40 sequencing is a sensitive and cost-effective method for detecting low-frequency variants.
- It shows promise for precision oncology applications.
- Further evaluation in real-world clinical settings is necessary.
